Pathologic correlation of 89Zr-Df-IAB2M antiprostate-specific membrane antigen (PSMA) minibody in patients with metastatic prostate cancer.

被引：0
|
作者：
Morris, Michael J.
Solomon, Stephen Barnett
Durack, Jeremy C.
O'Donoghue, Joseph A.
Lyashchenko, Serge K.
Ruan Shutian
Carrasquillo, Jorge A.
Lewis, Jason Stuart
Martinez, Danny F.
Parada, Nicole A.
Keppler, Jennifer
Wu, Anna
Reuter, Victor E.
Weber, Wolfgang
Scher, Howard I.
Larson, Steven M.
Pandit-Taskar, Neeta
机构：
[1] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA
[2] Mem Sloan Kettering Canc Ctr, Intervent Radiol & Image Guided Therapies, New York, NY 10021 USA
[3] ImaginAb Inc, Inglewood, CA USA
[4] Univ Calif Los Angeles, Dept Mol & Med Pharmacol, Crump Inst Mol Imaging, Los Angeles, CA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2015年 / 33卷 / 07期
关键词：
D O I：
10.1200/jco.2015.33.7_suppl.220
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
220
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Phase 1/2 dose escalation trial of the prostate-specific membrane antigen (PSMA)targeted immunoconjugate MLN2704 in patients with progressive metastatic castration-resistant prostate cancer (CRPC)
    Milowsky, MI
    Galsky, M
    Lewin, J
    Rozario, CP
    Owens, L
    Marshall, T
    Nanus, D
    Webb, IJ
    Scher, HI
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 406S - 406S
  • [32] A phase 2 trial of prostate-specific membrane antigen antibody drug conjugate (PSMA ADC) in taxane-refractory metastatic castration-resistant prostate cancer (mCRPC).
    Petrylak, Daniel Peter
    Smith, David C.
    Appleman, Leonard Joseph
    Fleming, Mark T.
    Hussain, Arif
    Dreicer, Robert
    Sartor, A. Oliver
    Shore, Neal D.
    Vogelzang, Nicholas J.
    Youssoufian, Hagop
    DiPippo, Vincent A.
    Stambler, Nancy
    Huang, Kathleen
    Israel, Robert Joseph
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [33] Phase I/II trial of the prostate-specific membrane antigen (PSMA)-targeted immunoconjugate MLN2704 in patients (pts) with progressive metastatic castration resistant prostate cancer (CRPC).
    Milowsky, M. I.
    Galsky, M.
    George, D. J.
    Lewin, J. M.
    Rozario, C. P.
    Marshall, T.
    Chang, M.
    Nanus, D. M.
    Webb, I. J.
    Scher, H. I.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 217S - 217S
  • [34] Targeted Alpha Therapy in mCRPC (Metastatic Castration-Resistant Prostate Cancer) Patients: Predictive Dosimetry and Toxicity Modeling of 225Ac-PSMA (Prostate-Specific Membrane Antigen)
    Belli, Maria Luisa
    Sarnelli, Anna
    Mezzenga, Emilio
    Cesarini, Francesco
    Caroli, Paola
    Di Iorio, Valentina
    Strigari, Lidia
    Cremonesi, Marta
    Romeo, Antonino
    Nicolini, Silvia
    Matteucci, Federica
    Severi, Stefano
    Paganelli, Giovanni
    FRONTIERS IN ONCOLOGY, 2020, 10
  • [35] Clinical outcomes with systemic therapy given after progression on prostate specific membrane antigen radioligand therapy (PSMA-RLT) in patients with metastatic castration-resistant prostate cancer (mCRPC).
    Salehi, Aida
    Fallah, Parvaneh
    Morin, Vincent G.
    Li, Meredith
    Probst, Stephan
    Ferrario, Cristiano
    Rose, April A. N.
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (4_SUPPL) : 78 - 78
  • [36] A phase 2 study of prostate specific membrane antigen antibody drug conjugate (PSMA ADC) in patients (pts) with progressive metastatic castration-resistant prostate cancer (mCRPC) following abiraterone and/or enzalutamide (abi/enz).
    Petrylak, Daniel Peter
    Vogelzang, Nicholas J.
    Chatta, Gurkamal S.
    Fleming, Mark T.
    Smith, David C.
    Appleman, Leonard Joseph
    Hussain, Arif
    Modiano, Manuel
    Singh, Parminder
    Tagawa, Scott T.
    Gore, Ira
    McClay, Edward Francis
    Mega, Anthony E.
    Sartor, A. Oliver
    Somer, Bradley G.
    Wadlow, Raymond Couric
    Shore, Neal D.
    Stambler, Nancy
    DiPippo, Vincent A.
    Israel, Robert Joseph
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (07)
  • [37] PROGNOSTIC VALUE OF NEUTROPHIL-TO-LYMPHOCYTE RATIO (NLR) IN PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (MCRPC) RECEIVING PROSTATE-SPECIFIC MEMBRANE ANTIGEN (PSMA) TARGETED RADIONUCLIDE THERAPY
    Stangl-Kremser, Judith
    Sun, Michael
    Ho, Benedict
    Thomas, Joseph
    Nauseef, Jones
    Osborne, Joseph
    Molina, Ana
    Sternberg, Cora
    Nanus, David
    Bander, Neil
    Tagawa, Scott
    JOURNAL OF UROLOGY, 2023, 209 : E384 - E385
  • [38] Prostate specific membrane antigen positron emission tomography (PSMA PET)-directed clinical outcomes in metastatic hormone-sensitive prostate cancer (mHSPC): Implications for the STAMPEDE2 trial design
    Abdel-Aty, H.
    Hujairi, N.
    Murray, I.
    Yogeswaran, Y.
    Murphy, L. R.
    Van As, N.
    Brown, L. C.
    James, N. D.
    ANNALS OF ONCOLOGY, 2023, 34 : S966 - S966
  • [39] Long-term adverse events (AE) in patients with metastatic castration-resistant prostate cancer (mCRPC) receiving prostate-specific membrane antigen (PSMA)-based targeted radionuclide therapy (TRT).
    Sun, Michael
    Thomas, Charlene
    Ho, Benedict
    Niaz, Muhammad Junaid
    Molina, Ana M.
    Sternberg, Cora N.
    Nanus, David M.
    Bander, Neil Harrison
    Tagawa, Scott T.
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [40] PROSTATE SPECIFIC MEMBRANE ANTIGEN ANTIBODY DRUG CONJUGATE (PSMA ADC) IN PATIENTS (PTS) WITH PROGRESSIVE METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (MCRPC) FOLLOWING ABIRATERONE AND/OR ENZALUTAMIDE (ABI/ENZ): RESULTS FROM A PHASE 2 STUDY
    Petrylak, Daniel
    Vogelzang, Nicholas
    Chatta, Kamal
    Fleming, Mark
    Smith, David
    Appleman, Leonard
    Hussain, Arif
    Modiano, Manuel
    Singh, Parminder
    Tagawa, Scott
    Gore, Ira
    McClay, Ed
    Mega, Anthony
    Sartor, Oliver
    Somer, Brad
    Wadlow, Raymond
    Shore, Neal
    Stambler, Nancy
    DiPippo, Vincent
    Israel, Robert
    JOURNAL OF UROLOGY, 2015, 193 (04): : E1040 - E1040
12345